UY38786A - Agonistas de receptores tipo toll - Google Patents

Agonistas de receptores tipo toll

Info

Publication number
UY38786A
UY38786A UY0001038786A UY38786A UY38786A UY 38786 A UY38786 A UY 38786A UY 0001038786 A UY0001038786 A UY 0001038786A UY 38786 A UY38786 A UY 38786A UY 38786 A UY38786 A UY 38786A
Authority
UY
Uruguay
Prior art keywords
toll
receptor agonists
type receptor
compounds
salts
Prior art date
Application number
UY0001038786A
Other languages
English (en)
Inventor
Omar Ahmad
Andrew Fensome
Ethan Lawrence Fisher
Rayomand J Unwalla
Jun Xiao
Lei Zhang
Erik Alphie Lachapelle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY38786A publication Critical patent/UY38786A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos imidazo-piridinilo, o una sal de estos aceptable desde el punto de vista farmacéutico, a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos y usos de dichos compuestos, sales y composiciones para el tratamiento de crecimiento celular anormal, que incluye cáncer, en un sujeto que lo necesita.
UY0001038786A 2019-07-17 2020-07-15 Agonistas de receptores tipo toll UY38786A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875465P 2019-07-17 2019-07-17
US202062961288P 2020-01-15 2020-01-15

Publications (1)

Publication Number Publication Date
UY38786A true UY38786A (es) 2021-02-26

Family

ID=71728839

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038786A UY38786A (es) 2019-07-17 2020-07-15 Agonistas de receptores tipo toll

Country Status (20)

Country Link
US (2) US11339159B2 (es)
EP (1) EP3999507A1 (es)
JP (1) JP7137733B2 (es)
KR (1) KR20220034862A (es)
CN (1) CN114364677A (es)
AU (1) AU2020315210B2 (es)
BR (1) BR112022000341A2 (es)
CA (1) CA3147266C (es)
CL (1) CL2022000032A1 (es)
CO (1) CO2022000259A2 (es)
CR (1) CR20220018A (es)
CU (1) CU20220003A7 (es)
EC (1) ECSP22003665A (es)
IL (1) IL289877A (es)
MX (1) MX2022000656A (es)
PE (1) PE20220342A1 (es)
TW (1) TWI755788B (es)
UY (1) UY38786A (es)
WO (1) WO2021009676A1 (es)
ZA (1) ZA202201330B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2022153157A1 (en) 2021-01-13 2022-07-21 Pfizer Inc. A crystalline form of 2-((4-amino-2-(ethoxymethyl)-6,7-dimethyl-1 h-imidazo[4,5-c]pyridin-1-yl)methyl)-2-methylpropane-1,3-diol free base
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ES2149276T3 (es) 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN1897948A (zh) 2003-10-03 2007-01-17 3M创新有限公司 烷氧基取代的咪唑并喹啉
WO2006009832A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8846710B2 (en) * 2005-02-23 2014-09-30 3M Innovative Properties Company Method of preferentially inducing the biosynthesis of interferon
CA2686163A1 (en) 2007-05-08 2008-11-13 Astrazenca Ab Imidazoquinolines with immuno-modulating properties
CN101918447B (zh) 2007-12-14 2014-06-11 布里斯托尔-米尔斯·斯奎布公司 人ox40受体的结合分子
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
PE20190515A1 (es) 2011-11-17 2019-04-10 Pfizer Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos
PT3134402T (pt) * 2014-04-22 2020-07-02 Hoffmann La Roche Compostos de 4-amino-imidazoquinolina
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
HUE053704T2 (hu) * 2014-12-08 2021-07-28 Hoffmann La Roche 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
KR102405099B1 (ko) 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
US10351582B2 (en) 2015-12-14 2019-07-16 Glaxosmithkline Biologicals, S.A. Pegylated imidazoquinolines
CN109071514B (zh) 2016-04-07 2021-07-06 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
BR112018070602A2 (pt) 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
US10533007B2 (en) * 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
US10562178B2 (en) 2016-11-16 2020-02-18 Wink Robotics Machine for beauty salon
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018220584A1 (en) 2017-06-02 2018-12-06 Pfizer Inc. Antibodies specific for flt3 and their uses
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists

Also Published As

Publication number Publication date
US11976064B2 (en) 2024-05-07
KR20220034862A (ko) 2022-03-18
US20220274986A1 (en) 2022-09-01
WO2021009676A8 (en) 2022-03-03
JP2022534125A (ja) 2022-07-27
AU2020315210A1 (en) 2022-02-03
MX2022000656A (es) 2022-02-16
CA3147266A1 (en) 2021-01-21
BR112022000341A2 (pt) 2022-04-12
CU20220003A7 (es) 2022-08-09
TWI755788B (zh) 2022-02-21
CL2022000032A1 (es) 2022-09-02
US11339159B2 (en) 2022-05-24
PE20220342A1 (es) 2022-03-14
EP3999507A1 (en) 2022-05-25
TW202116770A (zh) 2021-05-01
CA3147266C (en) 2023-09-12
IL289877A (en) 2022-03-01
CO2022000259A2 (es) 2022-01-17
AU2020315210B2 (en) 2023-01-12
CN114364677A (zh) 2022-04-15
CR20220018A (es) 2022-02-08
ECSP22003665A (es) 2022-02-25
ZA202201330B (en) 2022-10-26
WO2021009676A1 (en) 2021-01-21
US20210017172A1 (en) 2021-01-21
JP7137733B2 (ja) 2022-09-14

Similar Documents

Publication Publication Date Title
UY38786A (es) Agonistas de receptores tipo toll
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CL2020002748A1 (es) Inhibidores de cinasa dependientes de ciclina
CO2021009806A2 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria sobre cdk2
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
CO2017000222A2 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
AR093705A1 (es) Depsipeptido y sus usos
PE20180412A1 (es) Compuestos inhibidores de la senalizacion de la via de notch
ECSP19066134A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
UY36124A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida
CL2017003025A1 (es) Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
CO2023012903A2 (es) Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2)
CO2019015099A2 (es) Composiciones farmacéuticas
AR100177A1 (es) Derivados del 3-oxo-tetrahidro-furo[3,2-b]pirrol-4(5h)-ilo ii
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1